{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T23:07:48Z","timestamp":1773184068265,"version":"3.50.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T00:00:00Z","timestamp":1749772800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T00:00:00Z","timestamp":1749772800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"DOI":"10.1007\/s11255-025-04581-4","type":"journal-article","created":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T05:42:35Z","timestamp":1749793355000},"page":"4049-4056","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Comparison of microRNA-21 expression in bladder cancer tumor with normal-appearing adjacent tissue and healthy controls"],"prefix":"10.1007","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2135-6757","authenticated-orcid":false,"given":"Salman","family":"Soltani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2269-4109","authenticated-orcid":false,"given":"Hamid Reza","family":"Rahimi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8582-5658","authenticated-orcid":false,"given":"Mahdi","family":"Mottaghi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7831-8858","authenticated-orcid":false,"given":"Mahmoud","family":"Tavakkoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1526-3765","authenticated-orcid":false,"given":"Maryam","family":"Emadzadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1351-3142","authenticated-orcid":false,"given":"Atena","family":"Aghaee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6470-4096","authenticated-orcid":false,"given":"Sajjad","family":"Sadeghpour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7267-7446","authenticated-orcid":false,"given":"Hamidreza","family":"Ghorbani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,13]]},"reference":[{"key":"4581_CR1","unstructured":"SEER Cancer Stat Facts: Bladder Cancer. National Cancer Institute. Bethesda, MD 2024 [cited 2024 8-Dec]. Available from: https:\/\/seer.cancer.gov\/statfacts\/html\/urinb.html."},{"key":"4581_CR2","unstructured":"AmericanCancerSociety. Key Statistics for Bladder Cancer 2022 [updated 12-Jan-2022; cited 2022 23-Feb]. Available from: https:\/\/www.cancer.org\/cancer\/bladder-cancer\/about\/key-statistics.html."},{"key":"4581_CR3","doi-asserted-by":"publisher","first-page":"100326","DOI":"10.1016\/j.jcpo.2022.100326","volume":"32","author":"JC Michaeli","year":"2022","unstructured":"Michaeli JC, Boch T, Albers S, Michaeli T, Michaeli DT (2022) Socio-economic burden of disease: Survivorship costs for bladder cancer. J Cancer Policy 32:100326","journal-title":"J Cancer Policy"},{"issue":"19","key":"4581_CR4","doi-asserted-by":"publisher","first-page":"32370","DOI":"10.18632\/oncotarget.16026","volume":"8","author":"X Liu","year":"2017","unstructured":"Liu X, Liu X, Wu Y, Wu Q, Wang Q, Yang Z et al (2017) MicroRNAs in biofluids are novel tools for bladder cancer screening. Oncotarget 8(19):32370","journal-title":"Oncotarget"},{"key":"4581_CR5","unstructured":"PDQ\u00ae Screening and Prevention Editorial Board. PDQ Bladder and Other Urothelial Cancers Screening. Bethesda, MD: National Cancer Institute. Updated <07\/30\/2021>. Available at: https:\/\/www.cancer.gov\/types\/bladder\/patient\/bladder-screening-pdq. Accessed <04\/09\/2020>. [PMID: 26389218] ["},{"issue":"1","key":"4581_CR6","doi-asserted-by":"publisher","first-page":"5","DOI":"10.21037\/tau.2018.09.11","volume":"8","author":"MG Cumberbatch","year":"2019","unstructured":"Cumberbatch MG, Noon AP (2019) Epidemiology, aetiology and screening of bladder cancer. Trans Androl Urol 8(1):5","journal-title":"Trans Androl Urol"},{"issue":"2","key":"4581_CR7","first-page":"177","volume":"71","author":"P Kutwin","year":"2018","unstructured":"Kutwin P, Konecki T, Borkowska EM, Traczyk-Borszy\u0144ska M, Jab\u0142onowski Z (2018) Urine miRNA as a potential biomarker for bladder cancer detection\u2013a meta-analysis. Central Eur J Urol 71(2):177","journal-title":"Central Eur J Urol"},{"key":"4581_CR8","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","volume":"81","author":"M Babjuk","year":"2021","unstructured":"Babjuk M, Burger M, Capoun O, Cohen D, Comp\u00e9rat EM, Escrig JLD et al (2021) European association of urology guidelines on non\u2013muscle-invasive bladder cancer (ta, T1, and carcinoma in situ). Eur Urol 81:75\u201394","journal-title":"Eur Urol"},{"issue":"5","key":"4581_CR9","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1038\/nrurol.2010.45","volume":"7","author":"A Schaefer","year":"2010","unstructured":"Schaefer A, Stephan C, Busch J, Yousef GM, Jung K (2010) Diagnostic, prognostic and therapeutic implications of microRNAs in urologic tumors. Nat Rev Urol 7(5):286\u2013297","journal-title":"Nat Rev Urol"},{"issue":"12","key":"4581_CR10","first-page":"11659","volume":"10","author":"W Wang","year":"2017","unstructured":"Wang W, Yin Z (2017) Diagnostic value of long non-coding RNA H19, UCA1, and HOTAIR as promising biomarkers in human bladder cancer. Int J Clin Exp Pathol 10(12):11659","journal-title":"Int J Clin Exp Pathol"},{"key":"4581_CR11","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.omtn.2020.03.003","volume":"20","author":"D Bautista-S\u00e1nchez","year":"2020","unstructured":"Bautista-S\u00e1nchez D, Arriaga-Canon C, Pedroza-Torres A, De La Rosa-Vel\u00e1zquez IA, Gonz\u00e1lez-Barrios R, Contreras-Espinosa L et al (2020) The promising role of miR-21 as a cancer biomarker and its importance in RNA-based therapeutics. Mol Ther-Nucl Acids 20:409\u2013420","journal-title":"Mol Ther-Nucl Acids"},{"key":"4581_CR12","doi-asserted-by":"publisher","first-page":"1437951","DOI":"10.3389\/fcell.2024.1437951","volume":"12","author":"L Gan","year":"2024","unstructured":"Gan L, Zheng L, Zou J, Luo P, Chen T, Zou J et al (2024) MicroRNA-21 in urologic cancers: from molecular mechanisms to clinical implications. Front Cell Dev Biol 12:1437951","journal-title":"Front Cell Dev Biol"},{"issue":"15","key":"4581_CR13","doi-asserted-by":"publisher","first-page":"24668","DOI":"10.18632\/oncotarget.14969","volume":"8","author":"K Matsuzaki","year":"2017","unstructured":"Matsuzaki K, Fujita K, Jingushi K, Kawashima A, Ujike T, Nagahara A et al (2017) MiR-21-5p in urinary extracellular vesicles is a novel biomarker of urothelial carcinoma. Oncotarget 8(15):24668\u201324678","journal-title":"Oncotarget"},{"key":"4581_CR14","doi-asserted-by":"publisher","first-page":"101793","DOI":"10.1016\/j.genrep.2023.101793","volume":"32","author":"MS Rizk","year":"2023","unstructured":"Rizk MS, El-Hefnawy SM, Sultan SM, Torad HK, Ismail AE-HA, Fouda MN et al (2023) Biochemical and molecular study of extracellular MiR-21-5p and MiR-99-5p as diagnostic biomarkers of urothelial bladder carcinoma. Gene Reports. 32:101793","journal-title":"Gene Reports."},{"key":"4581_CR15","first-page":"475","volume":"30","author":"A Homami","year":"2016","unstructured":"Homami A, Ghazi F (2016) MicroRNAs as biomarkers associated with bladder cancer. Med J Islam Repub Iran 30:475","journal-title":"Med J Islam Repub Iran"},{"issue":"1","key":"4581_CR16","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1186\/s12885-021-08926-x","volume":"21","author":"H Lin","year":"2021","unstructured":"Lin H, Shi X, Li H, Hui J, Liu R, Chen Z et al (2021) Urinary Exosomal miRNAs as biomarkers of bladder Cancer and experimental verification of mechanism of miR-93-5p in bladder Cancer. BMC Cancer 21(1):1293","journal-title":"BMC Cancer"},{"issue":"1","key":"4581_CR17","doi-asserted-by":"publisher","first-page":"121","DOI":"10.31557\/APJCP.2023.24.1.121","volume":"24","author":"S Mamdouh","year":"2023","unstructured":"Mamdouh S, Sherif H, Romeih M, Elesaily K (2023) Urine micro-RNA signature as a potential non-invasive diagnostic biomarker in bladder cancer. Asian Pac J Cancer Prev 24(1):121\u2013131","journal-title":"Asian Pac J Cancer Prev"},{"issue":"1","key":"4581_CR18","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.eururo.2023.07.014","volume":"85","author":"T Strandgaard","year":"2024","unstructured":"Strandgaard T, Nordentoft I, Birkenkamp-Demtr\u00f6der K, Salminen L, Prip F, Rasmussen J et al (2024) Field Cancerization Is Associated with Tumor Development, T-cell Exhaustion, and Clinical Outcomes in Bladder Cancer. Eur Urol 85(1):82\u201392","journal-title":"Eur Urol"},{"issue":"6","key":"4581_CR19","doi-asserted-by":"publisher","first-page":"775","DOI":"10.21037\/tau.2019.07.11","volume":"8","author":"X Li","year":"2019","unstructured":"Li X, Gheinani AH, Adam RM (2019) A multi-omics approach to understanding the field effect in bladder cancer. Transl Androl Urol 8(6):775\u2013778","journal-title":"Transl Androl Urol"},{"issue":"7","key":"4581_CR20","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.21037\/tau-24-8","volume":"13","author":"DJ Rodden","year":"2024","unstructured":"Rodden DJ, Chung EH, Pittie R, Miyamoto DT (2024) Imposter among us: field cancerization in the bladder. Transl Androl Urol 13(7):1319\u20131323","journal-title":"Transl Androl Urol"},{"issue":"1","key":"4581_CR21","doi-asserted-by":"publisher","first-page":"11702","DOI":"10.1038\/s41598-017-11291-0","volume":"7","author":"MBH Thomsen","year":"2017","unstructured":"Thomsen MBH, Nordentoft I, Lamy P, Vang S, Reinert L, Mapendano CK et al (2017) Comprehensive multiregional analysis of molecular heterogeneity in bladder cancer. Sci Rep 7(1):11702","journal-title":"Sci Rep"},{"issue":"1","key":"4581_CR22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-016-0028-x","volume":"7","author":"Y Xie","year":"2017","unstructured":"Xie Y, Ma X, Chen L, Li H, Gu L, Gao Y et al (2017) MicroRNAs with prognostic significance in bladder cancer: a systematic review and meta-analysis. Sci Rep 7(1):1\u201312","journal-title":"Sci Rep"},{"issue":"6","key":"4581_CR23","first-page":"1721","volume":"25","author":"J Tao","year":"2011","unstructured":"Tao J, Lu Q, Wu D, Li P, Xu B, Qing W et al (2011) microRNA-21 modulates cell proliferation and sensitivity to doxorubicin in bladder cancer cells. Oncol Rep 25(6):1721\u20131729","journal-title":"Oncol Rep"},{"issue":"20","key":"4581_CR24","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gni178","volume":"33","author":"C Chen","year":"2005","unstructured":"Chen C, Ridzon DA, Broomer AJ, Zhou Z, Lee DH, Nguyen JT et al (2005) Real-time quantification of microRNAs by stem\u2013loop RT\u2013PCR. Nucleic Acids Res 33(20):e179","journal-title":"Nucleic Acids Res"},{"issue":"21","key":"4581_CR25","doi-asserted-by":"publisher","first-page":"8472","DOI":"10.1158\/0008-5472.CAN-09-0744","volume":"69","author":"JW Catto","year":"2009","unstructured":"Catto JW, Miah S, Owen HC, Bryant H, Myers K, Dudziec E et al (2009) Distinct microRNA alterations characterize high-and low-grade bladder cancer. Can Res 69(21):8472\u20138481","journal-title":"Can Res"},{"issue":"5","key":"4581_CR26","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.eururo.2011.01.044","volume":"59","author":"JW Catto","year":"2011","unstructured":"Catto JW, Alcaraz A, Bjartell AS, White RDV, Evans CP, Fussel S et al (2011) MicroRNA in prostate, bladder, and kidney cancer: a systematic review. Eur Urol 59(5):671\u2013681","journal-title":"Eur Urol"},{"key":"4581_CR27","doi-asserted-by":"crossref","unstructured":"Drakaki A, Koutsioumpa M, O'Brien NA, Vorvis C, Iliopoulos D, Slamon DJ. A chemically-modified miR-21 inhibitor (ADM-21) as a novel potential therapy in bladder cancer. American Society of Clinical Oncology; 2017.","DOI":"10.1200\/JCO.2017.35.6_suppl.335"},{"issue":"4","key":"4581_CR28","doi-asserted-by":"publisher","first-page":"283","DOI":"10.4103\/iju.IJU_4_17","volume":"33","author":"N Mitash","year":"2017","unstructured":"Mitash N, Agnihotri S, Tiwari S, Agrawal V, Mandhani A (2017) MicroRNA-21 could be a molecular marker to predict the recurrence of nonmuscle invasive bladder cancer. Indian J Urol 33(4):283\u2013290","journal-title":"Indian J Urol"},{"issue":"11","key":"4581_CR29","doi-asserted-by":"publisher","first-page":"4851","DOI":"10.1158\/0008-5472.CAN-08-4043","volume":"69","author":"L Dyrskj\u00f8t","year":"2009","unstructured":"Dyrskj\u00f8t L, Ostenfeld MS, Bramsen JB, Silahtaroglu AN, Lamy P, Ramanathan R et al (2009) Genomic profiling of microRNAs in bladder cancer: miR-129 is associated with poor outcome and promotes cell death in vitro. Can Res 69(11):4851\u20134860","journal-title":"Can Res"},{"issue":"2","key":"4581_CR30","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.juro.2012.03.122","volume":"188","author":"A Zaravinos","year":"2012","unstructured":"Zaravinos A, Radojicic J, Lambrou GI, Volanis D, Delakas D, Stathopoulos EN et al (2012) Expression of miRNAs involved in angiogenesis, tumor cell proliferation, tumor suppressor inhibition, epithelial-mesenchymal transition and activation of metastasis in bladder cancer. J Urol 188(2):615\u2013623","journal-title":"J Urol"},{"key":"4581_CR31","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.urolonc.2008.06.006","volume":"28","author":"LA Neely","year":"2010","unstructured":"Neely LA, Rieger-Christ KM, Neto BS, Eroshkin A, Garver J, Patel S et al (2010) A microRNA expression ratio defining the invasive phenotype in bladder tumors. Urol Oncol: Semin Origin Invest 28:39\u201348","journal-title":"Urol Oncol: Semin Origin Invest"},{"issue":"1","key":"4581_CR32","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1111\/cas.13856","volume":"110","author":"W Usuba","year":"2019","unstructured":"Usuba W, Urabe F, Yamamoto Y, Matsuzaki J, Sasaki H, Ichikawa M et al (2019) Circulating miRNA panels for specific and early detection in bladder cancer. Cancer Sci 110(1):408\u2013419","journal-title":"Cancer Sci"},{"issue":"1","key":"4581_CR33","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1002\/pros.23714","volume":"79","author":"N Ghorbanmehr","year":"2019","unstructured":"Ghorbanmehr N, Gharbi S, Korsching E, Tavallaei M, Einollahi B, Mowla SJ (2019) miR-21-5p, miR-141-3p, and miR-205-5p levels in urine\u2014promising biomarkers for the identification of prostate and bladder cancer. Prostate 79(1):88\u201395","journal-title":"Prostate"},{"issue":"4","key":"4581_CR34","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1038\/bjc.2015.472","volume":"114","author":"N Sapre","year":"2016","unstructured":"Sapre N, Macintyre G, Clarkson M, Naeem H, Cmero M, Kowalczyk A et al (2016) A urinary microRNA signature can predict the presence of bladder urothelial carcinoma in patients undergoing surveillance. Br J Cancer 114(4):454\u2013462","journal-title":"Br J Cancer"},{"key":"4581_CR35","doi-asserted-by":"crossref","unstructured":"Mobarra N, Raji S, Najafi S, Kafi FK, Ferns GA, Pakzad R. Hypoxia-Induced miR-210 Overexpression Promotes the Differentiation of Human-Induced Pluripotent Stem Cells to Hepatocyte-Like Cells on Random Nanofiber Poly-L-Lactic Acid\/Poly (\u03b5-Caprolactone) Scaffolds. Oxidative medicine and cellular longevity. 2021;2021.","DOI":"10.1155\/2021\/4229721"},{"key":"4581_CR36","unstructured":"Smithb PJMSG, Adcockc ALDIM, Greened NGMCM. The Estrogen-Induced miR-19 Downregulates Secretory Leucoprotease Inhibitor Expression in Monocytes. 2019."},{"issue":"18","key":"4581_CR37","doi-asserted-by":"publisher","first-page":"7165","DOI":"10.1158\/0008-5472.CAN-09-1448","volume":"69","author":"J Ribas","year":"2009","unstructured":"Ribas J, Ni X, Haffner M, Wentzel EA, Salmasi AH, Chowdhury WH et al (2009) miR-21: an androgen receptor\u2013regulated microRNA that promotes hormone-dependent and hormone-independent prostate cancer growth. Can Res 69(18):7165\u20137169","journal-title":"Can Res"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-025-04581-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-025-04581-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-025-04581-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T18:14:02Z","timestamp":1761848042000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-025-04581-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,13]]},"references-count":37,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4581"],"URL":"https:\/\/doi.org\/10.1007\/s11255-025-04581-4","relation":{},"ISSN":["1573-2584"],"issn-type":[{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,13]]},"assertion":[{"value":"18 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}